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Background: Poxvirus encodes up to four TNF decoy receptors (vTNFRs) thatmimic etanercept, an anti-TNF drug used in
the clinic.
Results: vTNFRs display differences in ligand specificity and inhibitory potency.
Conclusion: Some vTNFRs are more specific and potent TNF inhibitors than etanercept.
Significance: This study may help to understand the role of vTNFRs in pathogenesis and improve the anti-TNF
treatments.
The blockade of tumor necrosis factor (TNF) by etanercept, a
soluble version of the humanTNF receptor 2 (hTNFR2), is awell
established strategy to inhibit adverse TNF-mediated inflam-
matory responses in the clinic. A similar strategy is employed by
poxviruses, encoding four viralTNFdecoy receptor homologues
(vTNFRs) named cytokine response modifier B (CrmB), CrmC,
CrmD, andCrmE. These vTNFRs are differentially expressed by
poxviral species, suggesting distinct immunomodulatory prop-
erties. Whereas the human variola virus and mouse ectromelia
virus encode one vTNFR, the broad host range cowpox virus
encodes all vTNFRs.We report the first comprehensive study of
the functional and binding properties of these four vTNFRs,
providing an explanation for their expression profile among dif-
ferent poxviruses. In addition, the vTNFRs activities were com-
pared with the hTNFR2 used in the clinic. Interestingly, CrmB
from variola virus, the causative agent of smallpox, is the most
potent TNFR of those tested here including hTNFR2. Further-
more, we demonstrate a new immunomodulatory activity of
vTNFRs, showing that CrmB and CrmD also inhibit the activity
of lymphotoxin . Similarly, we report for the first time that the
hTNFR2 blocks the biological activity of lymphotoxin . The
characterization of vTNFRs optimized during virus-host evolu-
tion to modulate the host immune response provides relevant
information about their potential role in pathogenesis and may
be used to improve anti-inflammatory therapies based on solu-
ble decoy TNFRs.
The human TNF ligand superfamily (TNFSF)3 comprises 19
cytokines that signal through 29 cellular receptors included in
the TNF receptor superfamily (1). Among these, TNF (TNF)
and lymphotoxin  (LT) exert important immune functions
by their interaction with TNF receptor 1 and 2 (TNFR1 and
TNFR2). Like other TNFSF members, TNF is produced after
the enzymatic cleavage of a type II transmembrane TNF pre-
cursor that is processed by the TNF converting enzyme to
release the soluble cytokine (2). By contrast, LT is a secreted
homotrimer of three -subunits with no membrane precursor.
A related cytokine, LT, is a non-secreted membrane cytokine
that can appear in two different heterotrimers of  and  sub-
units, LT12 and LT21 (3). These two forms of LT signal
through a distinct and specific receptor, LT receptor (LTR)
(4).
The importance of TNFSF signaling networks in antiviral
defense is underpinned by the existence of numerous distinct
viral proteins specifically dedicated to their modulation. Poxvi-
ruses, a family of complex DNA containing enveloped viruses
that include important human and animal pathogens as well as
broadly used vaccine vectors, have developed an array of pro-
teins targeting TNF-induced intracellular pathways (5). A
unique strategy developed by poxviruses for the control of TNF
is the expression of secreted TNF binding proteins. The
tanapox virus protein 2L displays a major histocompatibility
complex I-like folding (6) and can bind TNF with high affinity
and inhibit its activity (7). Orthologues are found in the other
members of the Yatapoxvirus genus, Yaba-like disease virus
and yaba monkey tumor virus, and in the genera Suipoxvirus
and Cervidpoxvirus (7, 8). On the other hand, orthopoxviruses
express secreted proteins with sequence similarity to the ligand
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binding region of cellular TNFRs (9), and these viral homo-
logues have been included in a protein family termed viral
TNFRs (vTNFRs). Five different vTNFRs have been identified:
cytokine response modifier B (CrmB), CrmC, CrmD, CrmE,
and a viral homologue of CD30 (10–15). The ectromelia virus
(ECTV) CD30 interacts with CD30L to inhibit the CD30-
CD30L interaction and to signal through membrane CD30L,
causing down-regulation of the Th1 response (14). Neverthe-
less, the viral CD30 is not a major virulence factor in the classi-
cal mousepox model (16). The other four vTNFRs are able to
bind TNF and inhibit its biological activity by mimicking the
extracellular domain of the cellular TNFR1/2, as shown by the
crystal structure of CrmE, the sole vTNFR structure available
(17). A contribution of vTNFRs to poxvirus pathogenesis has
been shown by using recombinant vaccinia viruses (VACVs)
expressing CrmE, CrmB, or CrmC, which displayed increased
virulence in an intranasal mouse infection (18). Additionally a
CPXV lacking CrmB but not other vTNFRs displayed an
increased LD50 in infected mice (19). Finally, the Leporipoxvi-
rus myxoma virus expresses another vTNFR named M-T2,
whose absence resulted in reduced clinical signs of illness in
infected rabbits (20).
vTNFRs are differentially conserved among orthopoxviral
species, but the reasons for this variability are not defined.
Thus, variola virus (VARV), the causative agent of smallpox
(21), encodes one copy of a single active vTNFR, CrmB that can
efficiently inhibit human TNF and LT (22). CrmB is also the
only active vTNFR gene in monkeypox virus (MPXV) that har-
bors two copies of this vTNFR. On the other hand, some cow-
pox virus (CPXV) strains, with a broad host range and a current
public health concern despite its generally low virulence in
humans (23), encode all four vTNFRs, with the CrmB gene
present in two copies in their genomes. In ECTV, a strictmouse
pathogen where vTNFR gene conservation has been studied
across isolates, theCrmD gene is present in two copies, whereas
the remaining vTNFRs appear as pseudogenes (24–26). In
most VACV strains vTNFRs genes are either deleted or trun-
cated (27, 28), but strains Lister, Evans, and USSR encode both
CrmCandCrmE (18, 29). This pattern (summarized inTable 1)
suggests that vTNFRs have been gained or lost selectively
across poxviral isolates and reflects the intrinsic unique evolu-
tionary history of each isolate.
Importantly, vTNFRs are also differentially expressed during
infection in terms of time of expression and abundance. Thus,
CrmB orthologues appear to be expressed at early times of
infection in all viral species (10, 11), whereas in ECTV and
CPXV CrmD and CPXV CrmC are late genes (11). CPXV
CrmC is expressed to higher levels than CrmD, whereas CrmD
is produced in higher amounts by ECTV (12). Moreover,
although vTNFRs were defined as soluble TNF inhibitors,
CrmE from VACV encodes both soluble and membrane
vTNFR activity (18). These differences in the expression kinet-
ics and location together with the potential unique biochemical
properties of each vTNFRs could explain their different expres-
sion pattern among poxvirus species. However, the latter has
not been properly approached, and the characterization of the
binding ligands and specificity of vTNFRs remain incomplete.
Although previous studies on vTNFRs have been focused on a
single or only a few proteins, a comprehensive analysis of the
ligand host specificity of the vTNFRs and their orthologues to
explore the implications of this variability in virus-host interac-
tion is lacking. Furthermore, despite the structural similarity
among TNFSF members, the binding of vTNFRs to other
ligands distinct toTNFor LThas been scarcely analyzed.Here
we report the first comprehensive and comparative study of the
affinity and the inhibitory activity of six different vTNFRs for
TNF and LT frommouse and human origin. We also demon-
strate that CrmB and CrmD inhibit the biological activity of
LT, adding a new immunomodulatory function to vTNFRs.
Our study shows that there are significant specificity differ-
ences that may explain the vTNFR expression profiles among
poxvirus species.
TNF inhibition with antagonists is an effective strategy to
treat TNF-mediated chronic inflammatory diseases. In this
studywehave compared the biochemical properties of a soluble
version of the human TNFR2, named etanercept (30), with
those of the vTNFRs and found that some viral receptors are
more potent and specific TNF inhibitors than etanercept.
Experimental Procedures
Cells and Reagents—L929 were grown in 10% FCS DMEM.
Recombinant baculoviruses were grown in adherent Hi5
insect cells in 10% FCS TC-100 medium or suspension Hi5
cells maintained in Express Five (Life Technologies) medium
for the generation of recombinant baculovirus or protein
expression, respectively. Recombinant cytokines were obtained
fromR&DSystems andPeprotech Inc. The recombinant recep-
tor mTNFR1-Fc was purchased from R&D Systems.
Construction of Recombinant Baculoviruses—The coding
genes, lacking the signal peptide, were cloned into pFastBac1
(Life Technologies) for the generation of recombinant baculo-
virus. Genes were PCR-amplified from recombinant plasmids,
except for CrmD from CPXV strain Brighton Red (CPXV221;
GenBankTM accession number AAM13659), which was ampli-
fied from viral genomic DNA. CrmB (CPXV005; GenBankTM
AAA60952) and CrmC (CPXV191; GenBankTM AAM13631)
from CPXV strain Brighton Red were PCR-amplified from
pAH21 and pRA112 (22), respectively. CrmE (K3R; GenBankTM
AJ272008) from CPXV strain Elephantpox was amplified from
pMS3 (13). The CrmB gene (G2R; GenBankTM AAA60933)
from VARV strain Bangladesh 1975 was generated by site-di-
rected mutagenesis of the camelpox virus orthologue. Permis-
sion from the World Health Organization was granted to hold
VARV DNA, and its manipulation was performed in accord-
ance to the established rules. A plasmid containing this
sequence, pRA107, was used as template (22). pMS1 (13) was
used to amplify the CrmD gene (E6; GenBankTM AJ567688)
from ECTV strain Hampstead.
Viral genes were amplified by PCR using a pair of primers
containing BamHI and XhoI restriction sites at the 5- and the
3-termini, respectively. Genes were ligated to BamHI-XhoI-
digested pAL7 (31), a modified pFastBac1 vector bearing the
honeybee melittin signal peptide at the 5 termini and a C-ter-
minal V5-His6 tag. The resulting constructions were named as
pSP3 (ECTV CrmD), pSP8 (CPXV CrmE), pSP9 (CPXV
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CrmC), pSP10 (CPXV CrmB), pSP11 (CPXV CrmD), and
pSP12 (VARV CrmB).
The ligand binding domain of human TNFR2 (amino acids
23–257; GenBankTM BC052977) was amplified from pBhT-
NFR2 (kindly provided by Daniela Maennel, University of
Regensburg, Germany) and cloned into BamHI-NotI-digested
pFastBac1 to generate pRM4. The human IgG1 Fc fragment
was subcloned into pRM4 from pMS18 (14) using NotI and
SphI restriction enzymes. The resulting construct coding for
the extracellular domain of hTNFR2 fused to a human Fc was
named pRM6.
Recombinant baculoviruses were generated using the Bac-
to-Bac system (Life Technologies) (22). Viral stocks were
amplified by infectingHi5 cells at low viralmultiplicity of infec-
tion (0.1–0.01 pfu/cell) to obtain high titer baculovirus stocks
for protein production.
Protein Expression and Purification—Recombinant His-
tagged proteins were purified from supernatants of Hi5 cells
infected at high multiplicity using nickel-nitrilotriacetic acid
columns (Qiagen) (22). hTNFR2-Fc was purified using protein
A-coupled Sepharose (Sigma) followed by size exclusion chro-
matography. Protein stocks were dialyzed against PBS and
quantified by both BCAassay (Pierce) and gel densitometry and
stored at 80 °C. When both quantification methods did not
provide comparable protein concentration values, the concen-
tration obtained by gel densitometry was assumed for subse-
quent experiments.
Cytotoxicity Assays—The activity of recombinant vTNFRs
and hTNFR2-Fc against hTNF, hLT, mTNF, mLT,
mLT12, and mLT21 was tested by cytotoxicity assays on
L929 cells (13). Briefly, 20 ng/ml hTNF, hLT, andmTNFwere
incubated in the presence of increasing molar ratios of recom-
binant protein. Due to its low specific activity, mLT,
mLT21, andmLT12 were used at 780, 44, and 440 ng/ml,
respectively. After 1 h of incubation at 37 °C, mixtures were
added over L929 cells in 96-well plates, and actinomycin D
(Sigma) at 4 g/ml was supplemented. Cell viability was
assessed after 18 h by using the Cell Titer Aqueous One Solu-
tion kit (Promega) andmeasuring the absorbance (A) at 492 nm
with a Sunrise microplate reader (Tecan). Samples with cyto-
kine but without inhibitor (0% viability) were used to normalize
the background signal. After normalization, cell viability was
calculated as the ratio SampleA492/ControlA492, where Con-
trolA492 is the average absorbance from samples without cyto-
kine (media, 100% viability).
Surface Plasmon Resonance (SPR) Assays—SPR experiments
were performed using a Biacore X biosensor (GE Healthcare)
and immobilizing recombinant vTNFRs and hTNFR2-Fc to
CM4 chips (GE Healthcare) by amine coupling as described
(22). For the determination of affinity constants, receptors were
immobilized to a final response of 350–800 response units. At
least 10 different concentrations (in the range 0.1–200 nM) of
the cytokines were injected at 30 l/min in HBS-EP and the
collected sensorgramswere aligned and fitted to a 1:1 Langmuir
model using the software Biaevaluation 3.2. The kinetic con-
stants were determined from fittings containing no less than 6
concentration sensorgrams.
For SPR competition experiments, 2,000 response units of
mTNFR1-Fc (R&D) were immobilized on a CM4 chip. Increas-
ing concentrations of CrmE and CrmC were preincubated in
HBS-EP buffer with 30 nM concentrations of each cytokine dur-
ing 15 min on ice. The mixture was injected at 10 l/min over
the mTNFR1-Fc chip, and the response units at 10 s before the
end of the injection was recorded.
For the binding screening ofmouse TNFSF ligands to CrmD,
the cytokines (TNFSF3, LT (LT12); TNFSF4, OX40L;
TNFSF5, CD40L; TNFSF6, FasL; TNFSF7, CD27L; TNFSF8,
CD30L; TNFSF10, TRAIL; TNFSF11, RANKL; TNFSF12,
TWEAK; TNFSF13, APRIL; TNFSF14, LIGHT; TNFSF15,
TL1A) were injected at 100 nM in HBS-EP and a flow rate of 10
l/min over ECTV CrmD immobilized onto a CM4 chip to
high density (2000 response units).
Results
Expression and Purification of vTNFRs—In orthopoxviruses
four distinct secreted TNF-binding proteins with similarity to
the extracellular domain of cellular TNFRs have been de-
scribed. These are named CrmB, CrmC, CrmD, and CrmE, and
orthologues are conserved in different combinations among
viral species (Table 1) (32). The N-terminal region of vTNFRs
mimics the extracellular domain of TNFRs and corresponds to
their TNF binding moiety (17). In both cellular and viral
TNFRs, the N terminus contains up to four repetitions of cys-
teine-rich domains (CRDs). The cysteine residues, essential for
the folding of the CRDs, are highly conserved in the first three
CRDs, whereas the four canonical cysteines of the CRD4 of
hTNFR2 are inconsistently conserved in vTNFRs (Fig. 1A).
Nevertheless, the CRD4 is dispensable for ligand binding in
hTNFR2 (33), and CrmE is known to be a three-CRD contain-
ing vTNFR (17). For the other vTNFRs, we assumed the previ-
ously proposed CRD configuration, where CrmB and CrmD
have four and CrmC has three CRDs (10–12). Overall, signifi-
cant differences can be found in the primary sequences of the
TNF binding domain among vTNFRs (Fig. 1A). In fact, only
TABLE 1
vTNFR gene conservation in selectedOrthopoxvirus strains
na., not annotated in complete genome sequence; tr., truncated gene; -, gene absent.
Virus CrmB CrmC CrmD CrmE
CPXV GRI-90 D2L/I4Ra A56R K2R K3R
CPXV BRb CPXV005/CPXV226 CPXV191 CPXV221 na./(tr.)
ECTV NAVAL EVN002P (tr.)/EVN205P (tr.) EVN175P (tr.) EVN006/EVN201 EVN005P (tr.)/EVN202P (tr.)
VARV BSH75 G2R - - -
VACV Lister List002 (tr.)/List200 (tr.) List172 - List195
VACVWR VACVWR004 (tr.)/VACVWR215 (tr.) VACVWR179 (tr.) - -
a The names of the genes are indicated.
b BR, Brighton Red; BSH75, Bangladesh 1975; WR, Western Reserve.
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CrmD and CrmB share 50% amino acid identity in this
domain, whereas the identity of CrmE to any other vTNFR is
45% and down to 35% in the case of CrmC, the most diver-
gent vTNFR (Fig. 1B). To address the possible implications
of this diversity in terms of viral immunomodulation, we
have characterized these proteins further on a side-by-side
basis. In addition, as schematically depicted in Fig. 1C, CrmB
and CrmD contain an additional C-terminal extension, termed
the SECRET domain, that has been described as an indepen-
dent folding domain with the capacity to block chemokine
activity (22, 34), suggesting differential roles during infection as
compared with the CrmC and CrmE proteins that lack this
domain (Fig. 1C).
We expressed and purified the four different vTNFRs en-
coded by CPXV as well as variants derived fromVARV (CrmB)
and ECTV (CrmD) (Fig. 1C). The vTNFRs were expressed in
FIGURE 1. Expression of recombinant vTNFRs. A, sequence alignment using Clustal Omega of the TNF binding domains of ECTV CrmD (gene E6, strain
Hampstead,UniProt/TrEMBLaccessionno.O57300), CPXVCrmD (geneCPXV221, strainBrightonRed,UniProt/TrEMBLaccessionno.O57079), VARVCrmB (gene
G2R, strain Bangladesh 1975, UniProt/TrEMBL accession no. P34015), CPXV CrmB (gene CPXV005, strain Brighton Red, UniProt/TrEMBL accession no. Q85308),
CPXV CrmE (gene K3R, strain Elephantpox, UniProt/TrEMBL accession no. Q9DJL2), CPXV CrmC (gene CPXV191, strain Brighton Red, UniProt/TrEMBL accession
no. Q9YP87), and human TNFR2 (UniProt/TrEMBL accession no. P20333). The sequences were aligned without the signal peptide and split into the different
CRDs for clarity purposes. Cysteine residues are highlighted in each CRD. B, percentage of amino acid identity among the TNF binding domain of vTNFRs and
hTNFR2 determined by using the web server SIAS and the substitution matrix BLOSUM62. C, schematic representation of the baculovirus expressed vTNFRs.
The anti-TNFSF domain and the SECRET domain are indicated. Below, Coomassie Blue-stained gels showing 0.5–1 g of each purified vTNFR and hTNFR2-Fc.
Molecular mass is indicated in kDa.
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the baculovirus system fused toC-terminalV5 andHis tags, and
the secreted proteins were purified by affinity chromatography.
Additionally, we purified the hTNFR2-Fc protein (hTNFR2
hereon), a molecule known in the clinic as etanercept and used
for the treatment of TNF-mediated immune disorders. We
aimed to compare the inhibitory and binding abilities of this
anti-TNF drug with those of vTNFRs.
Anti-TNFSF Activity and Binding Affinity of vTNFRs—Over-
all, vTNFRs are known to bind either TNF alone or TNF as well
as LT. The proteins assessed here are derived from viruses
infecting human and/or rodents. Therefore, to obtain compar-
ative data for all purified vTNFRs,we performed SPR analysis to
determine their binding affinities for both human and murine
TNF and LT (Table 2). Some examples of the sensorgram
fittings performed to obtain the affinity constants are shown in
Fig. 2. The results confirmed the differentiation in two groups,
with the CrmB andCrmDproteins binding both TNF and LT,
whereas CrmC and CrmE were selective TNF binders. The
affinity constants for TNF were globally 1 order of magnitude
lower (100–2420 pM) than those calculated, when applicable,
for LT (3.11–50.40 nM). Remarkably, regarding LT affinities,
CrmB proteins showed a higher affinity for the human than for
the mouse ligand, whereas the opposite scenario was found for
CrmD proteins (Table 2). This observation hints at potential
viral adaptations to different hosts.
Binding of the ligands can result in the blockade of their
biologic activity, although this has been shown not always to be
the case for vTNFRs. For instance, theCrmEprotein bindsTNF
from different species while only inhibiting hTNF activity (13,
18). To obtain a complete understanding of the blocking capac-
ity of the proteins under study, we performed biological activity
assays. The addition of TNF or LT to L929 cells induces cell
death. In the presence of a blocking protein, cells will be pro-
tected from this effect, resulting in preservation of the cell
monolayer. As shown in Fig. 3, the four cytokines efficiently
induced cell death resulting in complete killing of the cells (0%
viability).
As expected, CrmE and CrmC did not protect cells from
hLT- or mLT-induced cytotoxicity (Fig. 3, C and D), in
accordance with their lack of binding for these ligands.
Although both CrmB and CrmD proteins effectively inhibited
the activity of mLT (Fig. 3C), only the CrmB proteins could
protect cells from hLT-induced cytotoxicity to some extent,
achieving 40–50% cell survival when incubated with a 200-fold
molar excess of vTNFR (Fig. 3D). This might reflect the higher
binding affinity for this ligand of the CrmB proteins (KD 7.56
and 3.11 nM) as compared with that of the CrmD proteins (KD
50.40 and 23.20 nM).
Despite the similar affinity of CrmB and CrmD proteins for
both hTNF andmTNF, interesting differences in their capacity
to block these cytokines were detected. CrmB proteins pro-
tected from mTNF-induced cell death best, with 80% cell via-
bility rates at a 1:5 molar ratio, whereas to achieve similar pro-
tection levels against hTNF, 1:50 ratios were required. Between
CrmDs, however, although the ECTV orthologue effectively
blocked both human andmurine TNF (requiring 50-foldmolar
excess to reach full protection levels), the CPXV-derived pro-
tein was a surprisingly poor TNF inhibitor, protecting 70 and
30% of cells when incubated with mTNF and hTNF, respec-
tively, at a 1:200 molar ratio. This phenomenon might be
related to the reduced half-life (t1⁄2) of the CPXV CrmD-TNF
complexes as compared with those of the ECTV CrmD-TNF
complexes (Table 2).
As previously shown, CrmE was unable to protect from
mTNF activity, whereas it protected from hTNF (Fig. 3, A and
B). In contrast to what previous data suggested (13, 18), CrmE
displayed high binding affinities for both mTNF (KD 0.26 nM)
and hTNF (KD 0.11 nM) (Table 2), suggesting that, unlike for
hTNF, the mTNF residues involved in the biological effect of
this cytokine are not efficiently blocked by CrmE. CrmC
showed the opposite specificity in terms of activity, inhibiting
the mTNF cytotoxic effect but not that of hTNF (Fig. 3, A and
B). This confirms previous findings obtained with CrmC-con-
taining supernatants fromVACV-infected cells (18). The activ-
ity of CrmC correlated with a relatively worse affinity for the
human ligand, with KD values of 0.15 and 2.42 nM, respectively
(Table 2), although differences in the binding mode might also
contribute to this effect.
TABLE 2
Kinetic parameters, derived affinity constants, and half-life (t1/2) of the binding of the recombinant vTNFRs to mTNF, hTNF, mLT, and hLT
a nbd., no binding detected.
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Importantly, although hTNFR2 bound all these ligands with
an affinity in the same range as the vTNFRs (Table 2), it was
found to be a much weaker inhibitor than vTNFRs (Fig. 3). The
purified hTNFR2 expressed in the baculovirus system had a
binding affinity for TNF similar to that of commercially avail-
able etanercept (not shown). Although the vTNFRs completely
blocked the activity of murine ligands, these were only partially
blocked (20 and 50% cell viability) by hTNFR2 at the highest
molar ratios tested (Fig. 3, A and C). In the case of the human
ligands, the degree of cell protection achieved with hTNFR2
was comparable to the vTNFRs activity at the highest dose (Fig.
3, B and D). However, CrmB, CrmD, and CrmE achieved com-
plete protection from hTNF-induced cytotoxicity at lower
doses than hTNFR2 (Fig. 3B). These results indicate that
vTNFRs aremore efficient anti-TNFSF proteins than one of the
antagonists used in the clinic to block TNF activity.
Differences in the Blockage of the mTNF-TNFR1 and hTNF-
TNFR1 Interaction Explain the Observed Specificity for CrmE
andCrmC—To understand the reason for the lack of inhibition
of hTNF activity by CrmC and mTNF by CrmE despite their
high binding affinities (KD 2.42 and 0.26 nM, respectively), we
next studied their ability to compete ligand-cell receptor inter-
actions. Thus, we assayed by SPR the capacity of CrmC and
CrmE to inhibit the interaction of mTNF and hTNF with
mTNFR1, the cellular receptor that drives their cytotoxic effect
on L929 cells (35). As shown in Fig. 4, increasing amounts of
recombinant CrmE and CrmC were able to compete the bind-
ing of mTNF and hTNF to the mTNFR1. Although both CrmE
and CrmC bind mTNF with similar high affinity, 40 nM CrmC
was sufficient to reduce by 50% the mTNF-TNFR1 binding,
whereas 160 nM CrmE was required to achieve a similar
degree of inhibition (Fig. 4A). The opposite situation was found
in the case of the hTNF-mTNFR1 interaction, where CrmE
was able to inhibit binding of hTNF to the receptor almost
completely, whereas CrmC only diminished it to 70% at the
highest dose tested (Fig. 4B). These results showed that
vTNFRs block the TNF binding to its cellular receptor and that
CrmE and CrmC bind hTNF andmTNF using different molec-
ular strategies in such a way that the residues involved in recep-
tor interaction are only efficiently blocked in hTNF andmTNF,
respectively, accounting for the observed differences in their
biological activities.
FIGURE 2. Surface plasmon resonance analysis of the TNFSF members binding to vTNFRs. Four examples of the binding sensorgrams and fittings
obtained for the determination of the kinetic constants of the TNFSF-vTNFR interactions: mTNF to CPXV CrmD (A), hTNF to CPXV CrmB (B), mLT to ECTV
CrmD (C), and hLT to VARV CrmB (D). Binding and dissociation of several concentrations of TNFSF ligands at 30 l/min were recorded and adjusted to
a 1:1 Langmuir fitting (solid lines). The nanomolar concentration corresponding to each sensorgram is indicated. The arrowhead points the end of the
injection.
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CrmD, CrmB, and hTNFR2 Bind mLT and Inhibit Its Cyto-
toxic Effect—Among the vTNFRs, CrmD and CrmB have been
described as TNF and LT inhibitors, whereas CrmC and
CrmE are known to bind TNF only as confirmed in our study.
However, vTNFRs may interact with other members of the
TNFSF, which comprises up to 19 structurally related ligands
(1). Specifically, CrmEwas shown not to interact with any other
TNFSF ligands besides TNF (13). Similarly, CD30L was proved
FIGURE3.TNFandLT inhibitoryactivityofvTNFRsandhTNFR2. Inhibitionof thecytotoxicity inducedbymTNF (A), hTNF (B),mLT (C), andhLT (D) in L929
cells in the presence of purified recombinant vTNFRs or hTNFR2 at the indicated cytokine:proteinmolar ratios. Cell viability was assessed as the absorbance at
492 nm using the Cell Titer Aqueous One Solution kit (Promega). Values were normalized with the absorbance recorded from samples containing only the
corresponding cytokine, and these were set to zero. Data are represented as the percentage relative to the absorbance in the absence of cytokine (media).
Means S.D. of triplicate samples of three representative experiments are shown.
FIGURE 4. Inhibition of hTNF andmTNF binding to mTNFR1 by CrmE and CrmC. SPR competition experiment of 30 nM mTNF (A) and hTNF (B) binding to
mTNFR1-coupled biosensor chips with increasing amounts of soluble CrmC (f) and CrmE (F). The percentage of binding refers to binding in the absence of
soluble vTNFRs. RU, response units.
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to be the only ligand of vCD30 (16). However, a similar analysis
has not been performed with the other vTNFRs yet. To search
for possible further ligands, we performed a screening by SPR
using CrmD from ECTV and all commercially available mem-
bers of themouse TNFSF. As shown in Fig. 5Awe found that, in
addition to mTNF, CrmD was able to bind mLT. This cyto-
kine is a membrane ligand that can appear in two different
heterotrimeric forms, LT12 and LT21 (3). We deter-
mined by SPR the affinity of CrmD and the other receptors for
these two forms of mLT. As shown in Table 3, CrmB, CrmD,
and hTNFR2 but not CrmE andCrmCbound both LT hetero-
trimers with affinities ranging from 14 to 100 nM. LT signals
through a distinct cell receptor, LTR (4). The interactionLT-
LTR is known to induce cell death in some adenocarcinoma
cell lines (36). L929 cells express LTR (37), and therefore, they
are likely to be susceptible to LT-induced cytotoxicity. Thus,
to study whether the observed vTNFR-mLT interactions
could result in the blockade of the mLT biological activity, a
cytotoxicity assay on L929 cells was set up. As shown in Fig. 5,B
and C, both forms of mLT effectively induced cytotoxicity,
which was differently inhibited by vTNFRs and hTNFR2. As
expected, CrmE and CrmC did not prevent the killing effect of
either mLT forms, whereas the CrmD and CrmB orthologues
inhibited LT heterotrimers in a dose-dependent manner (Fig. 5,
B and C). Interestingly, and in agreement with its higher affinity,
CrmB proteins were more active than the CrmD orthologues
against mLT21 (Fig. 5C). In contrast, the CrmD orthologues
werebettermLT12 inhibitors than theCrmBproteins (Fig. 5B).
In summary,we show thatCrmDandCrmBorthologues interfere
efficiently not only with the activity of TNF and LT but alsowith
that of their newly identified ligand, LT.
The hTNFR2 blocked the activity of these two forms of
mouse LT (Fig. 5, B and C), in accordance with its high affi-
nities determined by SPR (KD 17.9 and 10.1 nM). This is, to our
knowledge, the first evidence of a biological effect of TNFR2 on
the activity of LT.
FIGURE 5.mLT inhibitory activity of vTNFRs. A, CrmD binding screening tomouse TNFSF by SPR. Cytokines were injected at 100 nM in HBS-EP over a ECTV
CrmD coupled chip at 10 l/min. The binding to CrmD of all commercially available mouse TNFSF members, from mTNFSF3 (mLT, from mLT12) to
mTNFSF15 (mTL1A)was recorded. As a control,mTNFwas included in the screening. The arrowhead indicates the endof the injection. B andC, inhibition of the
cytotoxicity induced by mLT12 (B) and LT21 (C) in L929 cells in the presence of purified recombinant vTNFRs and hTNFR2 at the indicated increasing
cytokine:protein molar ratios. Values were normalized with the absorbance recorded from samples containing only the corresponding cytokine, and these
were set to zero. Data are represented as the percentage relative to the absorbance in the absence of cytokine (media). Means S.D. of triplicate samples of
three representative experiments are shown.
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Discussion
The blockade of TNF activity is a potent strategy of immune
modulation widely used in the clinic for the treatment of
inflammatory diseases such as rheumatoid arthritis or ankylos-
ing spondylitis. The finding that poxviruses have developed
during their coevolution with their hosts, a similar strategy
based on the secretion of different modified soluble versions
of host TNFRs to modulate the inflammatory response sug-
gests the importance of TNF during the pathogenesis of viral
infections.
To better understand the differential contribution of
vTNFRs to specific poxvirus-host interaction pairs and because
most vTNFRs to date had been studied individually and under
different conditions, we provide a direct comparison of the
inhibitory capabilities and binding affinities of all vTNFRs pro-
duced, purified, and assayed on a side by side basis. This greatly
expands our previous knowledge of the vTNFR family and
allows an accurate interpretation of their potential roles. Up to
date only the affinities of CrmB for hTNF, mTNF, and hLT (22,
29) and CrmC for hTNF and mTNF had been published (11,
29). In our analysis this has been expanded to these and new
ligands as well as to all six analyzed vTNFRs. Of note, these
preexisting affinity data agree with the affinities reported here
for those same interactions. Moreover, we describe a new
ligand for CrmB and CrmD, LT, and we report the vTNFRs
activity against a ligand not studied before, the mouse LT.
Additionally, we compared the activities of the vTNFRs with
those of a soluble cellular hTNFR2, or etanercept, a molecule
used in the clinic as a TNF antagonist, to help understand
potential determinants of specificity and activity differences.
CrmBandCrmDhave been shown to interactwith hLT (10,
12), but their interaction with mLT was not explored. We
have shown that CrmB and CrmD interact with high affinity
with both hLT and mLT. In contrast to previous observa-
tions (12), the CrmD orthologues failed to inhibit the cytotoxic
effect of hLT in our conditions. Loparev et al. (12) character-
ized CrmD as a hLT inhibitor, but they used low hLT con-
centrations at high CrmD:hLT ratios (starting at 250:1 and
reaching up to 4000:1). According to our data, CrmD ortho-
logues, which bind mLT with a KD in the nanomolar range,
display a significant increase in the KD for hLT. Interestingly,
CrmB orthologues from VARV and CPXV bind hLT with
higher affinity thanmLT and are the only vTNFRs that inhibit
to some extent the hLT biological function.We conclude that
CrmB is a much more potent hLT inhibitor than CrmD,
which may explain why a human virus such as VARV encodes
CrmB rather than CrmD. Complementarily, because the affin-
ity of CrmD-mLT interaction is higher than that of CrmB-
mLT, CrmD could be a more efficient vTNFR for the mouse
pathogen ECTV. Little is known about the role of LT in
defense against poxviruses, but the fact that the host-restricted
VARVandECTVencode vTNFRs that are active against LT in
a host-specific manner suggests an important function of this
cytokine in the anti-viral response.
In contrast, CrmE and CrmC only interact with TNF. It is
known that CrmE binds TNF from different species but only
inhibits hTNF (13). Accordingly, we show that the binding
affinities for both CrmE-hTNF and CrmE-mTNF interactions
are similarly high, but only the interaction with hTNF results in
an efficient cell protection. Surprisingly, despite this inability to
inhibit mTNF, CrmE enhances the viral virulence in a mouse
model when expressed from recombinant VACV (18). Interest-
ingly, CrmC displays the reverse specificity. Both hTNF and
mTNF are strongly bound by CrmC, whereas only the cytotox-
icity of mTNF is prevented by this protein. In this regard the
affinity constants did not anticipate the host specificity of
CrmC and CrmE. Nevertheless, we show that CrmE is more
efficient in blocking the hTNF-TNFR1 than themTNF-TNFR1
interaction, suggesting that only in the case of hTNF the resi-
dues involved in the receptor binding are efficiently blocked by
CrmE. In contrast, CrmC poorly affected the hTNF-TNFR1
interaction but disrupted the binding of mTNF. Therefore,
CrmC and CrmE are specific mTNF and hTNF inhibitors,
respectively, suggesting their expression pattern is related to
the host tropism of the corresponding viral strains. This oppo-
site specificity of CrmC and CrmE was previously described by
Reading et al. (18) with protein-containing supernatants; here
we confirm their observations with purified proteins and pro-
vide the affinity constants for the interaction of these vTNFRs
with mTNF and hTNF.
The differences in the anti-TNFSF ligand activity among
vTNFR orthologues have been vaguely explored. Similar to
VARV, CrmB is the sole vTNFR encoded by MPXV. Gileva et
al. (38) defined that, despite their high similarity, CrmB ortho-
logues from VARV, CPXV, and MPXV show different anti-
TNF properties, with the VARV orthologue being the most
potent hTNF inhibitor.We have not detected significant differ-
ences between VARV CrmB and CPXV CrmB, probably
TABLE 3
Kinetic parameters, derived affinity constants, and half-life (t1/2) of the binding of the two forms of mLT to ECTV CrmD, VARV CrmB, CrmC,
CrmE, and hTNFR2
Cytokine Receptor Ka (S.E.) Kd (S.E.) KD t1⁄2
1/Ms s1 nM min
mLT12 CrmD 1.03 105 (7.62 102) 1.72 103 (2.31 105) 16.7 6.7
CrmB 1.29 105 (1.84 103) 2.58 103 (4.85 105) 20.0 4.5
CrmC nbda nbd nbd nbd
CrmE nbd nbd nbd nbd
hTNFR2 2.93 105 (1.00 104) 5.24 103 (1.90 104) 17.9 2.2
mLT21 CrmD 4.25 104 (1.35 103) 4.27 103 (4.89 105) 100.0 2.7
CrmB 1.39 105 (1.59 103) 1.94 103 (2.62 105) 14.0 6.0
CrmC nbd nbd nbd nbd
CrmE nbd nbd nbd nbd
hTNFR2 2.96 105 (6.70 103) 3.00 103 (3.70 105) 10.1 3.8
a nbd, no binding detected.
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because we have studied the CrmB orthologue from CPXV
strain Brighton Red, whereas Gileva et al. (38) analyzed the
orthologue from CPXV strain GRI-90. The seven-amino acid
changes found between the TNF binding domain of the CrmB
orthologues of these CPXV strains may confer distinct inhibi-
tory activities. In fact, differing in only six residues, we have
shown that CPXV CrmD is a much weaker TNF inhibitor than
ECTV CrmD. This inefficient anti-TNF activity of the CrmD
from CPXV is probably compensated by other vTNFRs
expressed by this virus. In contrast, CrmD and CrmB are the
only vTNFRs in ECTV and VARV, respectively, and may have
been finely adapted during evolution to efficiently inhibit the
TNFSF ligands found in their hosts (mouse or human). Thus, in
the case of ECTV and VARV, a single vTNFRs seems to have
co-opted all the immune modulatory activities provided by up
to four different vTNFRs in CPXV.
We identify here a new ligand for vTNFRs, LT. Based on the
LT inhibitory activity of CrmB, Smith et al. (11) proposed that
CrmB might bind LT. However, the observation that LT
contains at least one -subunit does not prove that a LT
binder can interact with LT, as underpinned by the fact that
these cytokines signal through completely different receptors:
TNFR1, TNFR2, and HVEM for LT and LTR for LT (1, 3).
We found that CrmD andCrmB interact with high affinity with
the two forms of mLT, mLT12 and mLT21, and dem-
onstrated that they are able to block their activity. Although
little is known about the role of LT in anti-viral responses, it
has been shown to be essential in the defense against Theiler’s
murine encephalomyelitis virus (39). Our findings suggest that
LTmight play an important as yet undescribed role during the
host response to poxviral infections.
The results presented here, summarized in Fig. 6, illustrate
that every vTNFR possesses unique features of binding affinity
and specificity as well as varying degrees of biological activity
that are probably finely tuned in relationship with the infected
host as well as the complement of immune-modulating pro-
teins of each virus. As additional aspectswhen considering their
roles in pathogenesis, it is important to note that vTNFRs are
also differentially expressed during the time course of infection
and that possible differences in the location of the vTNFRs such
as the described expression of CrmE at the cell surface (18)may
also influence their role in vivo.
Etanercept, a soluble version of the cellular hTNFR2 used in
the clinic as an anti-TNF drug, was included in our experi-
ments. We demonstrate that hTNFR2 binds and inhibits both
mouse forms of LT. Regarding the human LT, hTNFR2 is
thought to interact only with the form LT21 (40), but there
are no data to confirm whether this interaction can actually
induce any intracellular signaling. Therefore, we report here
the first evidence of a biological effect of TNFR2 over LT that
might have implications for the study of the molecular mecha-
nisms of TNF-related inflammatory diseases treated clinically
or experimentally with TNFR2. Etanercept is used for the treat-
ment of diverse TNF-mediated inflammatory diseases to block
the excess of soluble TNF that causes an exacerbated inflam-
matory response (41). However, as shown here, this molecule
can inhibit not only TNF but also LT and LT, two potentially
unfavorable activities. Indeed, these cytokines are essential for
FIGURE 6. Summary of the inhibitory activity of vTNFRs against TNFSFmembers. A, vTNFR inhibitory activities diagram. The cytokines efficiently blocked
by each vTNFR are indicated in the corresponding group. B, summary of the binding and inhibitory activities of all the studied vTNFRs. , no inhibition
detected;	, partial inhibition;		, complete inhibition and low affinity (KD 10 nM);			, complete inhibition and high affinity (KD
 10 nM). Regarding the
column of mLT, activities of CrmD and CrmB are referred to mLT12 and mLT21, respectively.
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the control of immune homeostasis and infections (42, 43), and
an increased risk of infections, autoimmune disorders, and can-
cer are documented side effects of etanercept. Thus, molecular
redesign of this medicine seems to be necessary to target TNF
specifically and avoid undesirable effects. The required knowl-
edge for this aim could be extracted fromvTNFRs. For instance,
a CrmE-like modification of etanercept would be particularly
interesting to develop a more potent and specific anti-hTNF
drug and reduce its side effects.
In summary, we provide the first comprehensive character-
ization of the different anti-TNFSF ligand activities of the
vTNFR family. This analysis will help to better understand the
role of these molecules in poxvirus pathogenesis and the rele-
vance of TNFSF ligands in anti-viral defense. Additionally, the
comparative study of the different vTNFRs provides a reference
framework for the design of more powerful and specific anti-
TNF treatments to be used in the clinic.
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